Mural Competitors

Delisted . USA . 
Stock . Mural Oncology Plc
MURADelisted Stock   2.04  0.00  0.00%   
Mural Oncology Plc competes with BioXcel Therapeutics, Generation Bio, Jasper Therapeutics, Evaxion Biotech, and Verrica Pharmaceuticals; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Mural Oncology competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Mural Oncology to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

Mural Oncology vs SAB Biotherapeutics Correlation

Very good diversification

The correlation between Mural Oncology Plc and SABS is -0.35 (i.e., Very good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Mural Oncology Plc and SABS in the same portfolio, assuming nothing else is changed.

Moving against Mural Stock

  0.66T ATT Inc Aggressive PushPairCorr
  0.66KO Coca Cola Earnings Call This WeekPairCorr
  0.63PG Procter GamblePairCorr
  0.57XOM Exxon Mobil Corp Aggressive PushPairCorr
  0.53CAT CaterpillarPairCorr
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
1.052.043.03
Details
Intrinsic
Valuation
LowRealHigh
0.751.742.73
Details

Mural Oncology Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Mural Oncology and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of Mural and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Mural Oncology Plc does not affect the price movement of the other competitor.

High positive correlations

EVAX
+ 0.68
BTAI
EVAX
+ 0.68
JSPR
BCAB
+ 0.68
JSPR
BCAB
+ 0.68
EVAX
SABS
+ 0.57
VRCA
ATHE
+ 0.41
LIMN
  

High negative correlations

SABS
- 0.71
EVAX
ATHE
- 0.69
VRCA
BCAB
- 0.6
GBIO
EVAX
- 0.54
GBIO
SABS
- 0.53
ATHE
SABS
- 0.53
JSPR

Risk-Adjusted Indicators

There is a big difference between Mural Stock performing well and Mural Oncology Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Mural Oncology's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
BTAI  4.12 (0.16) 0.00 (0.26) 0.00 
 0.00 
 9.42 
(8.05)
 25.30 
GBIO  1.62 (0.03)(0.02) 0.05  2.18 
(1.89)
 3.39 
(3.99)
 12.30 
JSPR  4.02 (0.33) 0.00 (1.12) 0.00 
 0.00 
 7.73 
(8.14)
 31.75 
EVAX  4.59 (0.58) 0.00 (1.53) 0.00 
 0.00 
 9.43 
(8.42)
 37.88 
VRCA  5.49  1.23  0.23  0.62  4.67 
(6.74)
 13.76 
(9.24)
 52.65 
BCAB  7.30 (1.15) 0.00  0.63  0.00 
 0.00 
 15.28 
(18.87)
 66.15 
VERU  2.99  0.00  0.00  0.08  0.00 
 0.00 
 6.07 
(7.92)
 22.62 
LIMN  8.49  1.37  0.12 (0.45) 8.09 
(12.35)
 33.64 
(11.58)
 97.96 
ATHE  3.05 (0.19)(0.02) 0.00  3.85 
(3.26)
 7.69 
(5.01)
 17.55 
SABS  2.90  0.46  0.09 (2.84) 3.31 
(3.54)
 6.13 
(4.94)
 22.52 

Mural Oncology Competitive Analysis

The better you understand Mural Oncology competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Mural Oncology's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Mural Oncology's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
MURA BTAI GBIO JSPR EVAX VRCA BCAB VERU LIMN ATHE
 0.00 
 2.04 
Mural
 6.37 
 1.67 
BioXcel
 6.97 
 5.34 
Generation
 3.68 
 1.31 
Jasper
 0.86 
 3.44 
Evaxion
 12.59 
 6.04 
Verrica
 5.21 
 0.20 
Bioatla
 1.28 
 2.31 
Veru
 13.10 
 1.26 
Liminatus
 2.52 
 3.48 
Alterity
Market Volatility
(90 Days Market Risk)
Slightly risky
Unstable
Somewhat reliable
Very risky
Unstable
Relatively risky
Extremely Dangerous
Slightly risky
Out of control
Moderately volatile
Market Performance
(90 Days Performance)
Weakest
Weak
Weakest
Weakest
Weakest
Good
Weakest
Weakest
Mild
Weakest
Odds of Financial Distress
(Probability Of Bankruptcy)
Hazard
Risky
Risky
Small
Risky
Strong
Risky
Risky
Strong
Fair
Current Valuation
(Equity Enterprise Value)
Over Valued
Under Valued
Fairly Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Over Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Buy
Buy
Strong Buy
Strong Buy
Buy
Strong Buy
Strong Buy
Not Available
Buy
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Sell
Hold
Strong Sell
Strong Sell
Hold
Strong Sell
Strong Sell
Strong Sell
Cautious Hold
Current Ratio
N/A
12.25
17.93
9.56
6.47
1.25
7.48
4.62
N/A
7.07
Net Asset
169.39 M
38.34 M
231.2 M
79.9 M
12.48 M
54.13 M
52.42 M
29.84 M
2.83 M
46.03 M
Profit Margin
N/A
N/A
N/A
N/A
-0.71
-0.84
N/A
N/A
N/A
-2.23
EBITDA
(125 M)
(44.16 M)
(74.26 M)
(74.87 M)
(9.79 M)
(65.9 M)
(73.02 M)
(15.53 M)
(2.75 M)
(14.63 M)
Current Valuation
(19.94 M)
106.02 M
(27.47 M)
(10.58 M)
24.14 M
125.13 M
11.19 M
22.35 M
160.23 M
40.35 M
Price To Book
0.64
3.97
0.71
3.34
4.81
238.54
2.68
2.05
N/A
2.1
Operating Margin
N/A
-143.2
-20.2
N/A
0.4
0.11
N/A
N/A
N/A
-1.86
Retained Earnings
(159.37 M)
(650.2 M)
(703.04 M)
(240.87 M)
(118.54 M)
(307.03 M)
(486.04 M)
(317.3 M)
(17.52 M)
(225.89 M)
Current Asset
N/A
609.37 K
N/A
N/A
N/A
N/A
N/A
15.14 M
N/A
14.26 M
Five Year Return
N/A
N/A
N/A
N/A
N/A
N/A
N/A
3.55
N/A
N/A
Beta
2.97
0.2
2.01
3.09
0.3
1.44
1.06
-1.49
0.17
-0.016
Number Of Employees
116
37
115
27
46
71
61
20
N/A
9
Shares Outstanding
17.34 M
21.87 M
6.74 M
27.98 M
8.34 M
15.99 M
64.04 M
16.05 M
26.01 M
18.13 M
Cash Flow From Operations
(128.54 M)
(72.03 M)
(88.56 M)
(62.6 M)
(12.94 M)
(60.93 M)
(71.94 M)
(30.04 M)
(3.11 M)
(11.45 M)
Total Debt
8.02 M
102.95 M
93.56 M
1.81 M
10.1 M
45.94 M
836 K
3.12 M
5.12 M
155.46 K
Return On Equity
-1.04
-17.67
-0.81
-1.91
-0.65
-15.47
-8.14
-0.62
N/A
-0.43
Return On Asset
-0.49
-0.67
-0.27
-0.73
-0.26
-0.26
-1.05
-0.49
N/A
-0.28
Number Of Shares Shorted
417.44 K
1.37 M
2.07 K
3.64 M
105.48 K
299.01 K
4.74 M
735.15 K
68.1 K
335
Book Value Per Share
3.19
-4.45
7.51
0.41
2.61
-1.8
-0.53
1.25
N/A
0.0035
Current Liabilities
N/A
1.67 M
N/A
N/A
N/A
N/A
N/A
4.19 M
N/A
1.73 M
Total Asset
169.39 M
38.34 M
231.2 M
79.9 M
12.48 M
54.13 M
52.42 M
29.84 M
2.83 M
46.03 M
Short Ratio
3.5
2.36
0.03
3.43
1.31
1.54
2.1
3.59
0.11
0.02
Target Price
6.0
15.25
5.25
9.8
12.33
16.5
10.0
25.0
N/A
12.0
Debt To Equity
N/A
0.38
0.27
0.068
0.48
2.69
0.028
0.17
N/A
0.003
Shares Owned By Institutions
46.57
13.17
66.07
74.3
6.04
19.11
28.84
26.6
N/A
1.85
Market Capitalization
35.38 M
34.34 M
35.98 M
37.78 M
28.02 M
110.49 M
13.49 M
37.56 M
145.16 M
64.71 M
Price To Earning
N/A
-2.62
N/A
N/A
N/A
N/A
N/A
240.0
N/A
-4.84
Price To Earnings To Growth
N/A
-0.01
N/A
N/A
N/A
0.03
N/A
N/A
N/A
N/A
Price To Sales
N/A
45.66
2.36
N/A
3.66
3.58
4.22
3.11
N/A
11.9
Net Income
(128.51 M)
(59.6 M)
(131.67 M)
(71.27 M)
(10.57 M)
(76.58 M)
(69.78 M)
(22.73 M)
(2.9 M)
(12.15 M)
Earnings Per Share
-6.93
-9.72
-9.37
-5.82
-4.0
-2.87
-1.15
-1.07
-0.16
-0.63
Shares Owned By Insiders
13.41
4.2
14.29
1.04
18.38
51.84
11.07
9.78
82.68
N/A
Revenue
N/A
2.27 M
19.89 M
N/A
3.34 M
7.57 M
11 M
N/A
N/A
5.44 M
Working Capital
126.72 M
15.16 M
157.85 M
60.57 M
4.4 M
22.17 M
36.69 M
11.13 M
(15.79 M)
42.34 M
Cash And Equivalents
N/A
233.45 M
301.17 M
60.81 M
25.25 M
14.4 M
178.12 M
100.55 M
N/A
34.81 M
Cash Per Share
N/A
8.33
5.07
1.6
1.06
0.35
4.77
1.25
N/A
0.87
Gross Profit
N/A
(212 K)
(32.4 M)
N/A
7.65 M
20.66 M
(46.73 M)
5.85 M
N/A
5.31 M
Day Typical Price
2.04
1.65
5.34
1.33
3.49
6.39
0.2
2.36
1.38
3.51
Accumulation Distribution
N/A
37596.09
N/A
48645.65
2276.48
32736.47
213590.0
5593.13
2.9 M
116.82
Daily Balance Of Power
0.0
0.5882
0
(0.56)
(0.10)
(0.81)
0.33
(0.19)
(0.41)
(1.00)
Period Momentum Indicator
N/A
0.1
(0.40)
(0.05)
(0.03)
(0.87)
0.0099
(0.03)
(0.19)
(0.09)
Rate Of Daily Change
1.0
1.06
0.93
0.96
0.99
0.87
1.05
0.99
0.87
0.97
Day Median Price
2.04
1.64
5.34
1.34
3.51
6.56
0.2
2.39
1.44
3.53
Price Action Indicator
N/A
0.085
(0.20)
(0.05)
(0.09)
(0.95)
0.0099
(0.1)
(0.27)
(0.09)
Coefficient Of Variation
(3,262)
(4,933)
4991.24
(1,804)
(1,139)
575.19
(776.02)
(4,929)
1351.43
33238.8
Mean Deviation
0.3799
4.12
1.62
4.02
4.59
5.49
7.3
2.99
8.49
3.05
Jensen Alpha
(0.03)
(0.16)
(0.03)
(0.33)
(0.58)
1.23
(1.15)
0.0049
1.37
(0.19)
Total Risk Alpha
(0.10)
(0.72)
(0.22)
(0.88)
(1.22)
0.5212
(2.48)
(0.53)
(0.57)
(0.44)
Sortino Ratio
N/A
N/A
(0.02)
N/A
N/A
0.2335
N/A
N/A
0.1181
(0.02)
Downside Variance
N/A
N/A
5.42
N/A
N/A
33.45
N/A
N/A
79.82
16.27
Standard Deviation
0.6522
5.47
2.29
5.27
6.13
8.33
10.34
3.98
15.59
3.99
Kurtosis
16.81
1.22
1.9
1.46
1.84
5.5
2.38
0.912
15.26
0.6756
Potential Upside
0.9615
9.42
3.39
7.73
9.43
13.76
15.28
6.07
33.64
7.69
Treynor Ratio
0.6976
(0.26)
0.0505
(1.12)
(1.53)
0.6174
0.6275
0.0838
(0.45)
9.0E-4
Maximum Drawdown
4.78
25.3
12.3
31.75
37.88
52.65
66.15
22.62
97.96
17.55
Variance
0.4253
29.87
5.24
27.74
37.58
69.47
106.97
15.81
243.06
15.91
Market Risk Adjusted Performance
0.7076
(0.25)
0.0605
(1.11)
(1.52)
0.6274
0.6375
0.0938
(0.44)
0.0109
Risk Adjusted Performance
(0.03)
(0.01)
0.0226
(0.04)
(0.06)
0.1485
(0.09)
(0.01)
0.0688
0.0104
Skewness
(2.91)
0.4401
(0.12)
(0.52)
0.4469
1.7
(0.26)
(0.36)
3.18
0.0661
Semi Deviation
N/A
N/A
2.18
N/A
N/A
4.67
N/A
N/A
8.09
3.85
Information Ratio
(0.18)
(0.04)
(0.02)
(0.07)
(0.10)
0.1621
(0.14)
(0.05)
0.0677
(0.02)
Value At Risk
(0.48)
(8.05)
(3.99)
(8.14)
(8.42)
(9.24)
(18.87)
(7.92)
(11.58)
(5.01)
Expected Short fall
N/A
N/A
(1.89)
N/A
N/A
(6.74)
N/A
N/A
(12.35)
(3.26)
Downside Deviation
N/A
N/A
2.33
N/A
N/A
5.78
N/A
N/A
8.93
4.03
Semi Variance
N/A
N/A
4.77
N/A
N/A
21.79
N/A
N/A
65.39
14.82

Mural Oncology Competition Performance Charts

Five steps to successful analysis of Mural Oncology Competition

Mural Oncology's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Mural Oncology Plc in relation to its competition. Mural Oncology's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Mural Oncology in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Mural Oncology's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Mural Oncology Plc, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Mural Oncology position

In addition to having Mural Oncology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Long Short Funds Thematic Idea Now

Long Short Funds
Long Short Funds Theme
Funds or Etfs that are designed to hedge away market risk by investing in combination of bonds, stocks, derivative instruments as well as short positions to maximize returns irrespective of market conditions. The Long Short Funds theme has 47 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Long Short Funds Theme or any other thematic opportunities.
View All  Next Launch
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.

Other Consideration for investing in Mural Stock

If you are still planning to invest in Mural Oncology Plc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Mural Oncology's history and understand the potential risks before investing.
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY